All In Biotech

Drug Trial Radar · NCT04804605

Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis

A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects With Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Dec 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,220

Actual

Start

Feb 25, 2021

Primary completion

May 28, 2024

Study completion May 28, 2024

Sponsor

Lead sponsor
Arcutis Biotherapeutics, Inc.Industry
Sponsor type
Industry
First posted
Mar 18, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was a Phase 3, multicenter, open-label extension study of the long-term safety of roflumilast cream 0.15% (completers of studies ARQ-151-311 or ARQ-151-312 aged ≥6 years and ARQ-151-315 rollovers who turned 6 years of age on study) or roflumilast cream 0.05% (ARQ-151-315 rollovers aged 2 to 5 years). Participants with mild to moderate atopic dermatitis (AD) applied roflumilast cream once daily (qd) for up to 52 weeks.

Conditions

  • Atopic Dermatitis Eczema

Interventions

  • ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%Drug

    ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With ≥1 Treatment-emergent Adverse Event (TEAE)Time frame: Up to 52 weeks

Locations

92 sites in 2 countries. Site status is shown where the registry gives one.

  • Arcutis Clinical Site 112

    Birmingham, Alabama

  • Arcutis Clinical Site 73

    Birmingham, Alabama

  • Arcutis Clinical Site 63

    Scottsdale, Arizona

  • Arcutis Clinical Site 106

    Bryant, Arkansas

  • Arcutis Clinical Site 116

    Fort Smith, Arkansas

  • Arcutis Clinical Site 69

    Beverly Hills, California

  • Arcutis Clinical Site 81

    Inglewood, California

  • Clinical Site 08

    San Francisco, California

  • Arcutis Clinical Site 31

    Santa Monica, California

  • Arcutis Clinical Site 130

    Thousand Oaks, California

  • Arcutis Clinical Site 123

    Centennial, Colorado

  • Arcutis Clinical Site 59

    Coral Gables, Florida

  • Arcutis Clinical Site 72

    Coral Gables, Florida

  • Arcutis Clinical Site 79

    Delray Beach, Florida

  • Arcutis Clinical Site 103

    Hollywood, Florida

  • Clinical Site 04

    Jacksonville, Florida

  • Arcutis Clinical Site 15

    Largo, Florida

  • Arcutis Clinical Site 67

    Miami, Florida

  • Arcutis Clinical Site 95

    Miami, Florida

  • Arcutis Clinical Site 68

    Miami, Florida

  • Arcutis Clinical Site 29

    Sanford, Florida

  • Clinical Site 01

    Tampa, Florida

  • Arcutis Clinical Site 138

    Wellington, Florida

  • Arcutis Clinical Site 47

    Sandy Springs, Georgia

  • Arcutis Clinical Site 145

    Boise, Idaho

  • Arcutis Clinical Site 13

    Rolling Meadows, Illinois

  • Arcutis Clinical Site 93

    Clarksville, Indiana

  • Clinical Site 22

    Plainfield, Indiana

  • Arcutis Clinical Site 114

    West Lafayette, Indiana

  • Clinical Site 03

    Louisville, Kentucky

  • Arcutis Clinical Site 80

    Covington, Louisiana

  • Arcutis Clinical Site 85

    Lake Charles, Louisiana

  • Arcutis Clinical Site 24

    Metairie, Louisiana

  • Arcutis Clinical Site 76

    Rockville, Maryland

  • Arcutis Clinical Site 94

    Bay City, Michigan

  • Arcutis Clinical Site 88

    Clarkston, Michigan

  • Arcutis Clinical Site 58

    Clinton Township, Michigan

  • Arcutis Clinical Site 66

    Detroit, Michigan

  • Arcutis Clinical Site 132

    Troy, Michigan

  • Clinical Site 10

    New Brighton, Minnesota

Showing 40 of 92 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.